Physician profile
Judith Piros
NPI 1992720288
$9,126.10
in general payments reported to CMS, 2019-2025
22 companies · $1,887 in 2025
The $1,887 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,400 · 2020: $577 · 2021: $1,060 · 2022: $1,715 · 2023: $936 · 2024: $1,551 · 2025: $1,887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,853 · Long Term Medical Supply Or Device Loan: $504 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,852.94 |
| Long Term Medical Supply Or Device Loan | $504.00 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,061.35 | 2019-2025 | Clareon, Unity, Rocklatan |
| Sun Pharmaceutical Industries INC. | $1,529.35 | 2019-2025 | Cequa |
| Abbvie INC. | $887.91 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $811.93 | 2022-2025 | Scoutpro Osmolarity System, Miebo, Vyzulta |
| Allergan, INC. | $705.89 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $472.92 | 2021-2023 | Tecnis Iol |
| Biotissue Holdings INC. | $378.47 | 2019-2025 | |
| Aerie Pharmaceuticals, INC. | $333.67 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $294.92 | 2019-2023 | |
| New World Medical,INC. | $259.34 | 2019-2025 | Ahmed Glaucoma Valve, Streamline, Clearpath |
| Mallinckrodt Hospital Products INC. | $249.28 | 2020-2022 | |
| Shire North American Group INC | $213.10 | 2019 | |
| Oyster Point Pharma, INC. | $204.96 | 2022-2025 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $199.27 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $121.86 | 2022-2025 | Istent Infinite |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $109.73 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $74.30 | 2021-2022 | |
| Eyevance Pharmaceuticals LLC | $70.59 | 2019-2022 | |
| Dompe US, INC. | $56.61 | 2021-2025 | Oxervate |
| Harrow Eye, LLC | $39.60 | 2024-2025 | Vevye |
| Thea Pharma INC. | $36.89 | 2024-2025 | Iyuzeh |
| Ivantis, INC | $14.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judith Piros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.